Despite evidence for increased expression of ACE2 in patients with cardiovascular disease who are treated with ACE inhibitors (ACE-I) and angiotensin receptor blockers, the actual impact of these drugs on COVID-19 was reported to be controversial (Danser et al., 2020; Mancia et al., 2020). Here, ACE is linked to cardiovascular disorder.